Background: The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.
Methods: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR.
Results: Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values ≤ 0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.
Conclusions: In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.
Written by:
Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Are you the author?
Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University Hospital Basel, Basel, Switzerland.
Reference: Prostate Cancer Prostatic Dis. 2013 Sep 3. Epub ahead of print.
doi: 10.1038/pcan.2013.31
PubMed Abstract
PMID: 23999669
UroToday.com Prostate Cancer Section
